Polymyxin B Sulfate

硫酸多粘菌素B

Report date: 2023/01/13 20:00:32
NME

Base Information

Drug NamePolymyxin B Sulfate
Drug Alias Namepolymyxinum B多黏菌素B硫酸盐多粘菌素B硫酸酯polimixina B多粘菌素B硫酸盐 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCell membrane function inhibitors
TargetsNot applicable
Therapy Area/IndicationsWounds and InjuriesDrug-Related Side Effects and Adverse ReactionsCritical Illness +[5] 
Global Approved IndicationsBacterial Infections
Approved Indications in ChinaBacterial Infections
Original Approved Country/TerritoryUnited States
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncTty Biopharm Co LtdShanghai Asia Pioneer Pharmaceutical Co Ltd
Inactive CompaniesUniversity Of Puerto Rico
Active IndicationsDrug-Related Side Effects and Adverse ReactionsBacterial InfectionsInfections
Inactive IndicationsWounds and InjuriesCritical Illness

Other Information

ATC CodeA07AA05J01XB02S01AA18 +[5] 
Related LinksWikipediaDrugBankKEGG